

Special Issue

Extracellular Vesicles in Cancer Treatment: Opportunities and Challenges

Message from the Guest Editor

Extracellular vesicles (EVs) are cell-derived lipid bilayer membrane particles that represent an additional mechanism for cell-to-cell communication and has been studied as possible biomarkers for different diseases. Moreover, since discovering that EVs play a wide range of tumor-related processes and have the endogenous ability to protect their encapsulated material from the extracellular environment, overcome natural barriers, intrinsic cell targeting properties and circulation stability, the potential use of EVs as therapeutic nanoplatforms for cancer studies and drug delivery has attracted considerable interest. Despite multiple advantages, the application of EVs for anticancer therapy has been limited by technical issues, such as obtaining large-scale standardized preparations and relatively low loading of the desired bioagents. This Special Issue aims to collect the latest advanced studies of EVs in diagnosing and treating cancer diseases, sharing knowledge and data with readers and scientists working in this discipline to foster an effective and safe clinical translation of these unique intercellular delivery vehicles.

Guest Editor

Dr. Krizia Sagini

Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital, 0379 Oslo, Norway

Deadline for manuscript submissions

closed (15 December 2022)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/109269

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).